Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000595505 | SCV000706321 | uncertain significance | not provided | 2017-02-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001854058 | SCV002256052 | uncertain significance | Autosomal recessive ataxia, Beauce type; Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2021-07-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 500401). This variant has not been reported in the literature in individuals affected with SYNE1-related conditions. This variant is present in population databases (rs766846025, ExAC 0.01%). This sequence change replaces glycine with serine at codon 3064 of the SYNE1 protein (p.Gly3064Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. |